{"transactions":[{"id":739267,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:41:22.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1081,"price":13.1,"value":14161.1,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,723 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":32576,"source":{"system":"sec-edgar","filing":"0001677896-26-000008","document":"form4-06122026_080618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000008/form4-06122026_080618.xml","form_type":"4"}},{"id":763304,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":24300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":27934,"source":{"system":"sec-edgar","filing":"0001677896-26-000006","document":"form4-05262026_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000006/form4-05262026_040505.xml","form_type":"4"}},{"id":788301,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":12563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":87437,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":12563},"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788300,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date."}],"balance_after":87500,"derivative":{"exercise_price":13.43,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788299,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":400,"price":23.71,"value":9484.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":3634,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788298,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":9253,"price":22.6985,"value":210029.2205,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":4034,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788297,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":22839,"price":21.2155,"value":484540.8045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":13287,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788296,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":5196,"price":19.7812,"value":102783.1152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":36126,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788295,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":37375,"price":18.912,"value":706836.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":41322,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788294,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":12563,"price":8.04,"value":101006.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":78697,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788293,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":62500,"price":13.43,"value":839375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":66134,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":873592,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T21:24:17.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001677896-26-000002","document":"form4-03022026_090313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000002/form4-03022026_090313.xml","form_type":"4"}},{"id":970776,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-12T21:17:53.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1016,"price":4.1,"value":4165.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,634 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":3634,"source":{"system":"sec-edgar","filing":"0001470831-25-000410","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000147083125000410/form4.xml","form_type":"4"}},{"id":1290585,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-30T22:51:50.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001578563-25-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000029/primary_doc.xml","form_type":"4"}},{"id":1469345,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-25T20:08:58.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":13.43,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001578563-24-000320","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856324000320/primary_doc.xml","form_type":"4"}},{"id":4261441,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC & Chief Compliance Off"}}],"security":"Common Stock","published_at":"2017-07-06T16:47:14.000Z","date":"2017-07-03","kind":"sale","acquired":false,"shares":806,"price":2.35,"value":1894.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,500 shares acquired under the Egalet Corporation Employee Stock Purchase Plan on June 30, 2017."}],"balance_after":29514,"source":{"system":"sec-edgar","filing":"0001179110-17-010176","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017010176/edgar.xml","form_type":"4"}},{"id":4285037,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC & Chief Compliance Off"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-12T16:41:08.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date.   25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date.   The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date."}],"balance_after":50000,"derivative":{"exercise_price":2.38,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179110-17-008928","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017008928/edgar.xml","form_type":"4"}},{"id":4359861,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC & Chief Compliance Off"}}],"security":"Common Stock","published_at":"2017-04-04T17:05:27.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":806,"price":5.05,"value":4070.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":28820,"source":{"system":"sec-edgar","filing":"0001179110-17-005584","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017005584/edgar.xml","form_type":"4"}},{"id":4501458,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC & Chief Compliance Off"}}],"security":"Common Stock","published_at":"2017-01-04T16:58:19.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":806,"price":7.75,"value":6246.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":29626,"source":{"system":"sec-edgar","filing":"0001179110-17-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017000254/edgar.xml","form_type":"4"}},{"id":4528322,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC & Chief Compliance Off"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-08T16:30:42.000Z","date":"2016-12-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to one-fourth of the underlying shares on the first anniversary of the grant date and with respect to one-forty eighth of the underlying shares each month thereafter until fully vested."}],"balance_after":50000,"derivative":{"exercise_price":8.11,"expiration_date":"2026-12-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179110-16-032595","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911016032595/edgar.xml","form_type":"4"}},{"id":4585922,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC & Chief Compliance Off"}}],"security":"Common Stock","published_at":"2016-10-04T16:25:06.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":806,"price":7.56,"value":6093.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015."}],"balance_after":30432,"source":{"system":"sec-edgar","filing":"0001179110-16-030281","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911016030281/edgar.xml","form_type":"4"}}]}